According to a report on 06/03/2026, Cigna said that beginning 07/01/2026 it will discontinue coverage of GLP-1 weight-loss medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for roughly 67,700 employees in its U.S
We remain committed to guiding our patients toward achieving and maintaining a healthy weight, improved well-being, and an abundant life
At one of our visits, he looked at me and said, Doc, Im running out of options. So I prescribed him a medication that everyone today is calling a weight loss drug. Six months later, his disease was better controlled than it had been in ten years
Eating for Success: Fueling Weight Loss & Well-being on GLP-1s Navigating nutrition while using GLP-1 medications centers around one core principle: maximizing nutrient density
While effective for obesity management, ongoing research and vigilant patient monitoring are essential to address and mitigate potential risks associated with GLP-1 RAs [87] [88]